Loading…
GSK's $2.2bn acquisition of RAPT Therapeutics bolsters its immunology pipeline with a promising long-acting anti-IgE treatment for food allergies.
This article covers information on GSK PLC.
LON:GSKGSK has completed its acquisition of RAPT Therapeutics, a California-based clinical-stage biotech focused on inflammatory and immunologic diseases. The headline prize is ozureprubart, a long-acting anti-IgE monoclonal antibody in phase IIb, aimed at preventing food-allergy reactions before they happen.
It is a neat strategic fit. GSK already has reach with allergy prescribers, and management says ozureprubart complements its Respiratory, Immunology & Inflammation (RI&I) pipeline. The company has global rights to the programme, excluding mainland China, Macau, Taiwan and Hong Kong.
IgE (immunoglobulin E) is a clinically validated target in allergy. It is the only approved systemic approach that has shown the ability to protect patients from the harmful immune responses that drive severe reactions. Notably, around 94% of severe food allergies are IgE‑mediated.
Here’s the differentiator GSK is betting on: dosing. Current anti-IgE treatments typically require injections every 2 to 4 weeks. Ozureprubart’s profile suggests it could be dosed every 12 weeks. Fewer injections could support better adherence, especially important as most patients are children, and it may open up a new option for approximately 25% of patients who are currently ineligible for existing therapy.
In the US alone, over 17 million people are diagnosed with food allergies, with more than 1.3 million suffering severe reactions. Around 65% of severe cases are in children and adolescents. The burden shows up in emergency care too, with more than 3 million visits each year. Families are paying for it, literally – an estimated $33 billion in 2024.
Translated: a validated target, a big pool of patients, and meaningful practical advantages would make a compelling commercial story if the data land well.
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
31 viewsLikes
No ratings yet
Data from the phase IIb prestIgE trial, evaluating ozureprubart as monotherapy, are expected in 2027. GSK plans to focus phase III on both at‑risk adult and paediatric populations.
That means the key catalyst on efficacy, safety and dosing durability is still some way off. Until then, investors will be watching for interim operational updates and any signals on study enrolment, regulatory feedback, and the final phase III design.
GSK has paid a total cash consideration representing an approximate aggregate equity value of $2.2 billion. Net of cash acquired, the upfront investment is approximately $1.9 billion. GSK assumes global rights to ozureprubart outside of mainland China, Macau, Taiwan and Hong Kong, and will be responsible for success-based milestone and royalty payments due to RAPT’s partner, Shanghai Jeyou Pharmaceutical Co., Ltd.
No revenue or near-term financial contribution from ozureprubart is disclosed – fair enough at this stage, given the asset is mid-clinical and unapproved.
| Key item | Detail |
|---|---|
| Target | RAPT Therapeutics (clinical-stage immunology biotech) |
| Headline value | $2.2 billion aggregate equity value |
| Upfront (net of cash) | $1.9 billion |
| Lead asset | Ozureprubart (long-acting anti-IgE monoclonal antibody) |
| Indication focus | Prophylactic protection against food allergens |
| Dosing proposition | Potential every 12 weeks (vs current 2–4 weeks) |
| Phase IIb readout | Expected in 2027 (prestIgE, monotherapy) |
| Phase III focus | At‑risk adult and paediatric populations |
| Geography | Global rights excluding mainland China, Macau, Taiwan, Hong Kong |
| Additional economics | Success-based milestones and royalties to Shanghai Jeyou |
GSK underscores that ozureprubart complements its commercial footprint and prescriber base in allergy. That matters: the go-to-market in immunology often hinges on specialist engagement and patient-pathway know-how. A long-acting anti-IgE, if successful, could dovetail with GSK’s RI&I ambition to deliver longer-lasting protection in immune-mediated disease.
Management’s tone is confident. Kaivan Khavandi, who leads RI&I R&D for GSK, calls ozureprubart a promising asset and highlights the aim to deliver longer-lasting protection. It is a clear statement that durability and convenience are central to GSK’s thesis here.
This is a bold, focused bet on a long-acting anti-IgE that aims to make life easier for patients and caregivers while expanding eligibility. The market need is undeniable and the mechanism is validated – good foundations for a sizeable opportunity if the data cooperate.
On the flip side, investors will have to be patient. The readout is slated for 2027, China and certain territories are excluded, and future economics include milestones and royalties. Net-net, a strategically coherent move by GSK to deepen its immunology footprint, with value crystallisation dependent on clinical proof over the next several years.
Note: GSK includes a standard caution that forward-looking statements are subject to risks and uncertainties, as detailed in its annual and quarterly reports.
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.